ClinicalTrials.gg
Active, not recruitingNCT05949281REC1TEUpdated Jul 13, 2026

Repurposing Colchicine for Reduction of Residual Inflammatory Risk in Type 1 Diabetes

A Phase 2 interventional study of Colchicine 0.5 MG Oral Tablet and Placebo in Type 1 Diabetes, Cardiovascular Diseases and Chronic Inflammation, sponsored by Asger Lund, MD. Active, not recruiting at 1 site in Denmark. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-13.

Sponsored by Asger Lund, MD · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark — 30 open to participants now, 35 under way, 3 of them phase 3. Diabetes Mellitus, Type 1 · Denmark.

Enrollment
45th of 157
102 · median 40
Started
2023
with 8 others
Phase 2
16 of 196
4 open now
Primary completion
2031-01
later than 33 of 34 live
Registered
160th of 196
by date
Lead sponsor
4 of 196
Asger Lund, MD

Among the 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark, this one is the 45th largest by enrollment of the 157 interventional ones that give a count, is one of 9 that started in 2023, is one of 16 in phase 2, reaches primary completion later than 33 of the 34 other live ones, and was the 160th registered.

Diabetes Mellitus, Type 1

3,758 studies on the registry are indexed under Diabetes Mellitus, Type 1; 600 are open to participants now.

Browse Diabetes Mellitus, Type 1 studies →

Open to participants now

30 of the 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 417 Diabetes Mellitus, Type 1 studies recruiting now, 130 (31%) set no upper age limit and 261 (63%) stop at 75 or younger; 187 take children under 18; 66 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 196 studies in Diabetes Mellitus, Type 1 with a site in Denmark, or all of them as a file.
02

Study summary

The aim of this clinical trial is to evaluate if colchicine in addition to standard of care improves markers of inflammation and cardiovascular disease in persons with type 1 diabetes. Participants will be assigned to either 0,5 mg colchicine daily or placebo in a 1:1 ratio for 26 weeks with the possibility of an additional 26 week extension of the intervention period. After the treatment period, there will a 5-year follow-up on all available outcome measures via electronic patient records for those who took part in the extension.

Read the detailed description

The current study aims to evaluate the efficacy of 0.5 mg colchicine once-daily added to existing standard of care in persons with established type 1 diabetes, existing arteriosclerotic cardiovascular disease (CVD) or at high risk thereof and C-reactive protein (CRP) ≥ 2 mg/L. Specifically, the primary objective is to determine the effect of colchicine (0.5 mg/daily) on levels of CRP (as assessed by high-sensitivity assays) as compared with placebo following 26-52 weeks of treatment. Additionally, the study will investigate the short and long-term effects of colchicine treatment on other markers of CVD and inflammation, markers of metabolism and markers of glycemic control in type 1 diabetes, including glycated hemoglobin (HbA1c), time spent in hypoglycemia (level 1 glucose readings 3.0-3.8 mmol/L and level 2 glucose readings \< 3.0 mmol/L), target glycemia (glucose readings 3.9-10 mmol/L) and hyperglycemia (level 1 glucose readings 10.1-13.9 mmol/L and level 2 glucose readings > 13.9 mmol/L) together with measures of glycemic variability evaluated by continuous glucose monitoring (CGM), insulin dosage, risk of hypoglycemia, risk of diabetic ketoacidosis and body weight. During the 5-year follow-up, we will collect all available outcome measures via electronic patient records.

03

Conditions studied

  • Type 1 Diabetes
  • Cardiovascular Diseases
  • Chronic Inflammation
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type 1 diabetes for more than five years according to World Health Organization criteria
  • Age 18-80 years
  • \< 80 mmol/mol
  • Stable insulin therapy (defined as no change in insulin brand and no newly initiated continous subcutaneus insulin infusion (CSII) or multiple-daily injection (MDI) therapy) and, if applicable, stable usage of glucose monitoring technology (e.g., continous glucose monitor (CGM) or intermittently scanned CGM) ≥ 3 months with either MDI or CSII
  • CRP ≥ 2 mg/L (measured by high-sensitivity assay)
  • > 50 mL/min/L/1.73 m\^2
  • Either stable arteriosclerotic cardiovascular disease (ASCVD) (as defined by ischemic heart disease including previous acute myocardial infarction, acute coronary syndrome and coronary revascularization; other arterial revascularization procedures; stroke and ; aortic aneurysm; peripheral arterial disease, including carotid atherosclerosis)
  • and/or risk of cardiovascular (CV) death > 5 % within 10 years (i.e., high or very high CV risk) as defined by the European Society of Cardiology or 10-year CV risk ≥ 20 % (i.e., high CV risk) as according to 'Steno Type 1 Diabetes Risk Engine' (https://steno.shinyapps.io/T1RiskEngine/)

Exclusion criteria

Exclusion Criteria:

  • Hypoglycemia unawareness (inability to register low blood glucose) am modum Pedersen-Bjergaard, unless usage of CGM with alarm function
  • Liver disease with elevated plasma (ALT) > three times the (measured at screening with the possibility of one repeat analysis within seven days, and the last measured value as being conclusive)
  • History of cirrhosis, chronic active hepatitis or severe hepatic disease
  • Inflammatory bowel disease or chronic diarrhea
  • Pre-existing progressive neuromuscular disease or persons with creatinine kinase levels > three times the upper limit of normal (measured at screening with the possibility of one repeat analysis within a week, and the last measured value as being conclusive)
  • Cancer or lymphoproliferative disease unless in complete remission for > 5 years
  • therapy or state of chronic immunodeficiency, including infection with (HIV)
  • Blood dyscrasias (e.g., myelodysplastic syndromes or related hematological disorders)
  • Leukocyte cell count \< 3.0 X 10\^9/L
  • count \< 110 X 10\^9/L
  • Systemic (oral or intravenous), long-term therapy (topical or inhaled steroids are allowed)
  • Hemodialysis or peritoneal dialysis therapy (since colchicine cannot be removed by dialysis or exchange transfusion)
  • Renal or hepatic impairment treated with a P-gp inhibitor or a strong inhibitor
  • Intake of grapefruit juice during trial participation
  • Other concomitant disease or treatment that according to the investigator's assessment makes the person unsuitable for study participation
  • Alcohol/drug abuse
  • Fertile women not using hormonal (tablet/pill, depot injection of progesterone, subdermal gestagen implantation, hormone intrauterine devices (IUD), hormonal vaginal ring or transdermal hormonal patch), chemical (copper IUD) or mechanical (condom, femidom, sterilization)
  • Pregnant or nursing women
  • On permanent treatment with colchicine that is not discontinued within 30 days of screening visit
  • Known or suspected to colchicine
  • Receipt of any drug within 30 days prior to screening visit
  • Simultaneous participation in any other clinical intervention trial
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
102 participants (actual)

Study arms

  • Active comparator
    Colchicine

    Colchicine tablet 0.5 mg once-daily

    Drug: Colchicine 0.5 MG Oral Tablet

  • Placebo comparator
    Placebo

    Placebo tablet once-daily

    Drug: Placebo

Interventions

  • DrugColchicineStudies of ColchicineColchicine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Colchicine 0.5 mg once-daily

    Also known as: Colrefuz

  • DrugPlacebo

    Placebo tablet once-daily

06

What researchers measure

Primary outcomes

  1. Change in fasting serum/plasma concentrations of C-reactive protein (CRP) measured by a high-sensitivity assay (hsCRP) (mg/L)

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment)

Secondary outcomes

  1. Change in fasting serum/plasma concentrations of C-reactive protein (CRP) measured by a high-sensitivity assay (hsCRP) (mg/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)

  2. Change in fasting serum/plasma concentrations of hemoglobin A1c (mmol/mol)

    %-point

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)

  3. Time spent in target blood glucose range (3.9 - 10 mmol/L) evaluated by a continous glucose monitor (CGM)

    (% of 24 hours)

    Time frame: From week 0 (baseline) to week 26 (end of treatment) or to 52 weeks (extension)

  4. Time spent in hyperglycemia level 1 (10-13.9 mmol/L) evaluated by a continous glucose monitor (CGM)

    (% of 24 hours)

    Time frame: From week 0 (baseline) to week 26 (end of treatment) or to 52 weeks (extension)

  5. Time spent in hyperglycemia level 2 (> 13.9 mmol/L) evaluated by a continous glucose monitor (CGM)

    (% of 24 hours)

    Time frame: From week 0 (baseline) to week 26 (end of treatment) or to 52 weeks (extension)

  6. Time spent in hypoglycemia level 1 (3.0-3.8 mmol/L) evaluated by a continous glucose monitor (CGM)

    (% of 24 hours)

    Time frame: From week 0 (baseline) to week 26 (end of treatment) or to 52 weeks (extension)

  7. Time spent in hypoglycemia level 2 (< 3.0 mmol/L)evaluated by a continous glucose monitor (CGM)

    (% of 24 hours)

    Time frame: From week 0 (baseline) to week 26 (end of treatment) or to 52 weeks (extension)

  8. Insulin dosage

    Number of units/day (both long- and short-acting insulin analogues)

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)

  9. Change in body weight (kg)

    %-point

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)

  10. Change in waist:hip ratio

    %-point

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)

  11. Change in fasting serum/plasma concentrations of low-density lipoprotein cholesterol (LDL) (mmol/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)

  12. Change in fasting serum/plasma concentrations of interleukin (IL)-6 (pg/mL)

    %-point

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)

  13. Change in fasting serum/plasma concentrations of tumor necrosis factor alpha (pg/mL)

    %-point

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)

  14. Safety-related events

    Serious adverse events (SAE), events of severe hypoglycemia, events of diabetic ketoacidosis

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)

Other outcomes

  1. Change in fasting serum/plasma concentrations of fibrinogen (µmol/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)

  2. Change in fasting serum/plasma concentrations of serum amyloid A (mg/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)

  3. Change in fasting serum/plasma concentrations of haptoglobin (g/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)

  4. Change in fasting serum/plasma concentrations of interleukin (IL)-1β (pg/mL)

    %-point

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)

  5. Change in fasting serum/plasma concentrations of interleukin (IL)-2 (pg/mL)

    %-point

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)

  6. Change in fasting serum/plasma concentrations of intercellular adhesion molecule 1 (ICAM-1) (pg/mL)

    %-point

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)

  7. Change in fasting serum/plasma concentrations of vascular cell adhesion molecule 1 (VCAM-1) (pg/mL)

    %-point

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)

  8. Change in fasting serum/plasma concentrations of total leukocyte count, including neutrophil, lymphocyte, basophil and eosinophil counts (10^9/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)

  9. Change in neutrophil:lymphocyte ratio

    %-point

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)

  10. Change in fasting serum/plasma concentrations of very low-density lipoprotein (VLDL) cholesterol (mmol/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)

  11. Change in fasting serum/plasma concentrations of high-density lipoprotein (HDL) cholesterol (mmol/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)

  12. Change in fasting serum/plasma concentrations of total cholesterol (mmol/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to 56 weeks (extension)

  13. Change in fasting serum/plasma concentrations of triglycerides (mmol/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to week 56 (extension)

  14. Change in fasting serum/plasma concentrations of lipoprotein (a) (mg/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (safety follow-up) or to week 56 (extension)

  15. Change in thrombocyte function measured by thromboelastography

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment) or to week 52 (extension)

  16. Change in fasting serum/plasma concentrations of N-terminal pro-brain natriuretic peptide (pro-BNP) (pmol/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  17. Change in consultation blood pressure (mmHg)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  18. Change in heart rate (beats/minute)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  19. Change in fasting serum/plasma concentrations of estimated glomerular filtration rate (eGFR) (mL/min/1.73 m2)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  20. Change in fasting serum/plasma concentrations of albumin (g/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  21. Change in urine albumin-to-creatinine ratio (mg/g)

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment) or to week 56 (extension)

  22. Change left ventricular (LV) mass index evaluated by cardiovascular ultrasonography (g/m^2)

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment)

  23. Change left ventricular (LV) septal wall thickness evaluated by cardiovascular ultrasonography (mm)

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment)

  24. Change left ventricular (LV) posterior wall thickness evaluated by cardiovascular ultrasonography (mm)

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment)

  25. Change left ventricular (LV) ejection fraction (LVEF) evaluated by cardiovascular ultrasonography (%)

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment)

  26. Change ratio of peak velocity blood flow from left ventricular relaxation in early diastole (E) to peak velocity flow in late diastole caused by atrial contraction (A) (E/A ratio) evaluated by cardiovascular ultrasonography

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment)

  27. Change early diastolic mitral inflow velocity (e') evaluated by cardiovascular ultrasonography (m/sec)

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment)

  28. Change ratio of early diastolic mitral inflow velocity (e') to early diastolic mitral annulus velocity (E) (E/e' ratio) evaluated by cardiovascular ultrasonography

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment)

  29. Change ratio of early mitral inflow velocity (E) to global diastolic strain rate (e' sr) (E/e'sr ratio) evaluated by cardiovascular ultrasonography

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment)

  30. Change left atrial volume (LAVi) evaluated by cardiovascular ultrasonography (mL)

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment)

  31. Change global longitudinal strain (GLS) evaluated by cardiovascular ultrasonography (%)

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment)

  32. Change aortic distensibility evaluated by cardiovascular ultrasonography (mmHg^-1)

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment)

  33. Change aortic strain evaluated by cardiovascular ultrasonography (%)

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment)

  34. Change in mean glucose evaluated by a continous glucose monitor (mmol/L)

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment) or to week 52 (extension)

  35. Change in standard deviation evaluated by a continous glucose monitor (mmol/L)

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment) or to week 52 (extension)

  36. Change in coefficient of variance evaluated by a continous glucose monitor (> 0.36 defined as glycemic variability)

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment) or to week 52 (extension)

  37. Change in glycemic variability (continuous overall net glycemic action (CONGA)) evaluated by a continous glucose monitor

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment) or to week 52 (extension)

  38. Change in mean amplitude of glycemic excursion evaluated by a continous glucose monitor

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment) or to week 52 (extension)

  39. Change in diabetes treatment satisfactory questionnaire, status version (DTSQs) (From 0 (min) to 6 (max), higher scores indicate a better outcome )

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  40. Change in diabetes treatment satisfactory questionnaire, change version (DTSQc) (From -3 (min) to 3 (max), higher scores indicate a better outcome)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  41. Change in audit of diabetes-dependent quality of life questionnaire (ADDQoL) (From -9 (min) to 9 (max), higher scores indicate a better outcome )

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  42. Change in fasting serum/plasma concentrations of ketones (mmol/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  43. Adverse events

    As reported by participants

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  44. Change in liver fat content as per the CAP score (dB/m) measured by FibroScan®

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment) or to week 52 (extension)

  45. Change in liver fibrosis score (kPa) measured by FibroScan®

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment) or to week 52 (extension)

  46. Change in fibrosis-4 (FIB-4) score (numerical scale, higher scores indicate a higher risk of fibrosis)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  47. Change in fatty liver index (FLI) score (numerical scale, higher scores indicate a higher risk of fibrosis)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  48. Change in fasting serum/plasma concentrations of hemoglobin (mmol/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  49. Change in fasting serum/plasma concentrations of thrombocytes (10^9/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  50. Change in fasting serum/plasma concentrations of glucose (mmol/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  51. Change in fasting serum/plasma concentrations of potassium (mmol/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  52. Change in fasting serum/plasma concentrations of sodium (mmol/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  53. Change in fasting serum/plasma concentrations of creatinine (umol/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  54. Change in fasting serum/plasma concentrations of alanine aminotransferase (U/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  55. Change in fasting serum/plasma concentrations of aspartate aminotransferase (U/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  56. Change in fasting serum/plasma concentrations of bilirubin (umol/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  57. Change in fasting serum/plasma concentrations of amylase (units/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  58. Change in fasting serum/plasma concentrations of creatine kinase (U/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  59. Change in fasting serum/plasma concentrations of C-peptide (pmol/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  60. Change in fasting serum/plasma concentrations of glucagon (pmol/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  61. Change in fasting serum/plasma concentrations of C-terminal telopeptide (ng/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  62. Change in fasting serum/plasma concentrations of procollagen type 1 N-terminal propeptide (ng/L)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  63. Change in body composition by bioimpedance analysis

    %-point (fat free mass, total fat mass, muscle mass, bone mass)

    Time frame: From week 0 (baseline) to week 26 (end of treatment) or to week 52 (extension)

  64. Change in body mass index (kg/m^2)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  65. Change in waist circumference (cm)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  66. Change in hip circumference (cm)

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  67. Change in waist:hip ratio

    %-point

    Time frame: From week 0 (baseline) to week 30 (end of treatment) or to week 56 (extension)

  68. Change in interleukin messenger ribonucleic acid (mRNA) expression measured by quantitative polymerase chain reaction

    %-point

    Time frame: From week 0 (baseline) to week 26 (end of treatment) or to week 56 (extension)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The study protocol has previously been published [DOI: 10.1111/dom.70139]. De-identified individual participant data will be available from publication of this article indefinitely upon request to the corresponding author from researchers who provide a methodologically sound proposal. To gain access to the data, the researchers will need to sign a data sharing agreement and/or collaborative agreement.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Jan 2031, 88 months after the start.

Of 83 non-industry phase 2 interventional studies under Diabetes Mellitus, Type 1, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 76. This study's planned 88 months is above that.

Counting every sponsor, half of 134 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2023
First posted
Jul 18, 2023
StartActual
Aug 29, 2023
Primary completionEst.
Jan 15, 2031
CompletionEst.
Jan 15, 2031
Last update
Jul 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05949281
Lead sponsor
Asger Lund, MD
Collaborators
University of Copenhagen, Juvenile Diabetes Research Foundation
Responsible party
Asger Lund, MD (Ass. Professor, MD, PhD, University Hospital, Gentofte, Copenhagen) — Sponsor-investigator
First posted
Jul 18, 2023
Start date
Aug 29, 2023
Primary completion
Jan 15, 2031 (estimated)
Completion
Jan 15, 2031 (estimated)
Last update
Jul 13, 2026

Study contacts

Asger B. Lund, MD, PhD
principal investigator · Center for Clinical Metabolic Research, Gentofte Hospital, Denmark

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Colchicine

Start the discussion